René Lammers Appointed Chief Research & Innovation Officer of The Estée Lauder Companies
The Estée Lauder Companies Inc. (NYSE: EL) today announced the appointment of René Lammers, Ph.D. as Executive Vice President, Chief Research & Innovation Officer, effective October 1, 2025. Mr. Lammers will report directly to Stéphane de La Faverie, President and Chief Executive Officer, and will join the company’s Executive Team.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250911004836/en/
René Lammers, Ph.D., Executive Vice President, Chief Research & Innovation Officer
“René is an exceptional and innovative leader whose deep scientific expertise, global perspective, and passion for cutting-edge product development will be instrumental as we transform our approach to research and innovation to more fully align with our focus on consumer centricity,” said Mr. de La Faverie. “Creating transformative innovation is integral to our strategic vision of Beauty Reimagined, and with René’s leadership, we are elevating our capabilities to deliver even more breakthrough new products as well as on-trend innovation more quickly across prestige price tiers. With this appointment, I am excited that my Executive Team is now complete and positioned to lead the company into its next chapter of growth and transformation.”
As Chief Research & Innovation Officer, Mr. Lammers will lead the evolution of The Estée Lauder Companies’ global Research & Innovation capabilities, including product and clinical innovation, scientific affairs, regulatory strategy, and upstream technologies across the company’s brand portfolio. He will help advance the company’s high-touch innovation model, bringing forward disruptive technologies and new science-based platforms that elevate performance, quality, safety, and sustainability. He will oversee the company’s Research and Innovation Centers worldwide and place a focus on delivering fast-to-market, on-trend innovation across in-demand subcategories, benefits and occasions. He will also advance collaborations with leading global scientific and academic institutions, and drive further external innovation with strategic partners, particularly in critical areas like biotechnology and longevity science.
Drawing on nearly 30 years of experience, Mr. Lammers brings a rare blend of deep scientific expertise with a passion for serving consumers, making him an ideal leader to Create Transformative Innovation, which is one of the action plan priorities of Beauty Reimagined. His consumer-first mindset and proven ability to develop and scale global innovations will help unlock new growth across categories and channels while reinforcing its legacy of scientific excellence and consumer trust.
Mr. Lammers joins The Estée Lauder Companies from PepsiCo, where he most recently served as Executive Vice President and Chief Science Officer, overseeing a 3,000-person global Research & Development organization. There, he created and scaled some of the world’s most beloved food and beverage products, shaping innovations that reached and delighted diverse consumers across the globe. He spearheaded PepsiCo’s science and technology agenda, scaling billion-dollar platforms, and driving breakthrough innovation and sustainability advances that blended scientific rigor with consumer insights. Prior to PepsiCo, René held senior leadership positions at Unilever, where he developed pioneering technologies across personal care, home care, and laundry, and established innovation hubs across Europe and Asia.
Mr. Lammers holds a Ph.D. in organic chemistry from Delft University of Technology and a master’s degree from Leiden University. He currently serves on the Board of the New York Hall of Science and is a Commissioner for the National Commission on Innovation and Competitiveness Frontiers, an initiative of the U.S. Council on Competitiveness.
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include those in the various quotations. Although the Company believes that its expectations are based on reasonable assumptions within the bounds of its knowledge of its business and operations, actual results may differ materially from the Company’s expectations. Factors that could cause actual results to differ from expectations include the ability to successfully implement the Company’s strategy, including Beauty Reimagined and the profit recovery and growth plan; successfully transition its leadership; and those other factors described in the Company’s filings with the Securities and Exchange Commission, including its most recent filings with the Securities and Exchange Commission. The Company assumes no responsibility to update forward-looking statements made herein or otherwise.
About The Estée Lauder Companies
The Estée Lauder Companies Inc. is one of the world’s leading manufacturers, marketers, and sellers of quality skin care, makeup, fragrance, and hair care products, and is a steward of luxury and prestige brands globally. The Company’s products are sold in approximately 150 countries and territories under brand names including: Estée Lauder, Aramis, Clinique, Lab Series, Origins, M·A·C, La Mer, Bobbi Brown Cosmetics, Aveda, Jo Malone London, Bumble and bumble, Darphin Paris, TOM FORD, Smashbox, AERIN Beauty, Le Labo, Editions de Parfums Frédéric Malle, GLAMGLOW, KILIAN PARIS, Too Faced, Dr.Jart+, the DECIEM family of brands, including The Ordinary and NIOD, and BALMAIN Beauty.
ELC-C
ELC-L
View source version on businesswire.com: https://www.businesswire.com/news/home/20250911004836/en/
Contacts
Media Relations:
Brendan Riley
briley@estee.com
Investor Relations:
Rainey Mancini
rmancini@estee.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Visa Unveils New Global Stablecoins Advisory Practice15.12.2025 13:00:00 CET | Press Release
Visa (NYSE: V), a global leader in digital payments, today announced the launch of its Stablecoins Advisory Practice. The new value-added service offering by Visa Consulting & Analytics (VCA) provides actionable insights and recommendations to guide banks, fintechs, merchants, and businesses of all sizes on market fit, strategy, and implementation. As the stablecoin market cap surpasses $250 billion, Visa’s settlement volume has accelerated, reaching a $3.5 billion annualized run rate as of November 30. Businesses are turning to Visa’s new Stablecoins Advisory Practice to unlock growth opportunities. “Putting our members first has always been our mission, and we’re committed to exploring innovations that strengthen financial health and convenience for those we serve. Stablecoins may represent an opportunity to enhance speed and lower cost in payments, so with the support of Visa, we are evaluating how this technology could fit into our broader strategy to deliver meaningful value to ou
SK Capital Announces Definitive Agreement to Invest in Swixx BioPharma AG to Drive the Next Phase of Growth and Global Expansion15.12.2025 12:30:00 CET | Press Release
SK Capital Partners, LP (“SK Capital”), a New York-based private investment firm focused on the life sciences, specialty materials, and ingredients sectors, today announced that its affiliate has reached an agreement to invest in Swixx BioPharma AG (“Swixx” or the “Company”) to accelerate the Company’s next phase of growth and global expansion. The investment values the Company in excess of EUR €1.5 billion. Swixx is the global leader in rest-of-world pharmaceutical commercialization services dedicated to delivering innovative, life-saving medications to underserved and hard-to-reach markets. Stuart Swanson and Petr Němec, Swixx’s Co-Founders, and Jean-Michel Lespinasse and Petr Pipal, Swixx’s CEO and CFO, respectively, will all retain significant ownership stakes in Swixx as part of the transaction. Existing institutional investors HBM Healthcare Investments, a Swiss-listed investment company for the global healthcare market, and Mérieux Equity Partners, a leading healthcare-specializ
Safe Software Recognized as a Niche Player in 2025 Gartner® Magic Quadrant™ for Data Integration Tools15.12.2025 12:00:00 CET | Press Release
Safe Software, a global leader in data integration and transformation, has once again been recognized in the 2025 Gartner® Magic Quadrant™ for Data Integration Tools, marking the sixth consecutive year the company has been included in this prestigious report. Safe Software’s FME Platform has evolved well beyond its geospatial roots to become the only All-Data, Any-AI Integration Platform, empowering organizations worldwide to connect all data, applications, and AI technologies anywhere, at any scale, and with complete flexibility. With a community of more than 200,000 enthusiastic users and 25,000+ organizations in over 125 countries, FME continues to redefine data integration by delivering a no-code enterprise solution that unifies data movement, automation, and AI connectivity. “Our continued recognition reflects the trust of our customers and the innovation of our team,” said Don Murray, CEO and Co-Founder of Safe Software. “We’re proud to help organizations integrate data seamlessl
GENESIS Pharma announces a new partnership with Otsuka Pharmaceutical Europe Ltd. for the commercialization of donidalorsen for hereditary angioedema in Central and Eastern Europe15.12.2025 10:00:00 CET | Press Release
ANNOUNCEMENT FOR EUROPEAN MEDICAL & PHARMACEUTICAL TRADE MEDIA AND EUROPEAN FINANCIAL MEDIA ONLY GENESIS Pharma, a regional biopharma company focused on the commercialization of innovative medicines in Central and Eastern Europe, announces an exclusive agreementwithOtsuka Pharmaceutical Europe Ltd. (OPEL), the European operation of global healthcare company Otsuka Pharmaceutical Co., Ltd., for donidalorsen. Under the terms of the agreement, GENESIS Pharma will exclusively distribute and commercializedonidalorsen in fourteen markets: Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Greece, Hungary, Latvia, Lithuania, Malta, Poland, Romania, Slovakia and Slovenia. In November 2025, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for donidalorsen in the routine prevention of recurrent attacks of hereditary angioedema (HAE) in adults and adolescents aged 12 years and older. The CHMP opinion is c
BitGo yn Sicrhau Cymeradwyaeth OCC i Drosi i Fanc Ymddiriedolaeth Genedlaethol Siartredig Ffederal13.12.2025 02:13:00 CET | Pressmeddelande
Cyhoeddodd BitGo Holdings, Inc. (“BitGo”), y cwmni seilwaith asedau digidol, heddiw fod Swyddfa Rheolwr yr Arian Cyfred (“OCC”) wedi cymeradwyo ei gais i drosi BitGo Trust Company, Inc., cwmni ymddiriedolaeth siartredig De Dakota, i fanc cenedlaethol o'r enw BitGo Bank & Trust, National Association (N.A.). Gyda chymeradwyaeth OCC heddiw o'i drosi, mae is-gwmni Cwmni Ymddiriedolaeth BitGo bellach yn gweithredu fel BitGo Bank & Trust, National Association (N.A.). Bydd BitGo Bank & Trust, N.A. yn gweithredu o dan un gyfundrefn oruchwylio ffederal unffurf, gan ei alluogi i ddarparu'r eglurder, y llywodraethiant, a'r sicrwydd rheoleiddiol y mae sefydliadau'n eu disgwyl gan ymddiriedolwr a reoleiddir yn ffederal. Mae'r gymeradwyaeth hon yn atgyfnerthu safle BitGo fel sylfaen sefydliadol ar gyfer y system ariannol fodern, gan gyfuno goruchwyliaeth ar lefel banc â'r diogelwch, y cydymffurfiaeth, a'r graddadwyedd sy'n diffinio seilwaith BitGo. O dan siarter y banc cenedlaethol, ac yn amodol ar
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom